Researchers have announced that TAVALISSE® (fostamatinib disodium hexahydrate) has been approved in Brazil for treating adults with chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatments. This new medication offers a different approach to managing ITP, a condition where the immune system mistakenly destroys platelets, leading to an increased risk of bleeding. The approval is significant for those in Brazil suffering from this chronic condition, as it provides a much-needed alternative treatment option.

For individuals with ITP, maintaining a stable platelet count is crucial for preventing serious complications, including severe bleeding. In clinical trials, 18% of patients taking fostamatinib achieved a stable platelet response, compared to just 2% of those on a placebo. Additionally, 43% of patients on fostamatinib showed an overall response, indicating that this medication could significantly improve the quality of life for many adults struggling with ITP.

The evidence for fostamatinib’s effectiveness comes from two large, phase III clinical trials involving 150 participants. These trials demonstrated that fostamatinib could provide a stable platelet count for those who had previously not responded to other treatments. While the results are promising, it is important to note that this medication is still relatively new and ongoing monitoring of its long-term effects will be necessary.

If you or someone you know is dealing with chronic ITP, it may be worth discussing this new treatment option with a healthcare provider, especially if previous therapies have not been effective. Always consult a medical professional before making any changes to treatment plans.

Source: globenewswire.com